Related Experiment Videos
Schizophrenia and drug delivery systems
Y H Cheng1, L Illum, S S Davis
1West Pharmaceutical Services, Drug Delivery and Clinical Research Centre Ltd, Nottingham Science and Technology Park, UK.
Journal of Drug Targeting
|June 14, 2000
Summary
Poor patient compliance with antipsychotic medications for schizophrenia often leads to relapse. Novel drug delivery systems offer a promising solution to improve treatment adherence and outcomes.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a severe, chronic brain disorder requiring ongoing management.
- Antipsychotic medications are crucial but face challenges with patient compliance due to side effects and dosing frequency.
- Conventional dosage forms (tablets, capsules) require frequent administration (2-4 times daily).
Purpose of the Study:
- To review the characteristics of schizophrenia and its pathophysiology.
- To discuss current drug therapy for schizophrenia.
- To explore the development and future of neuroleptic drug delivery systems.
Main Methods:
- Literature review of schizophrenia pathophysiology and drug therapy.
- Analysis of current antipsychotic drug delivery systems.
- Exploration of novel drug delivery system concepts for antipsychotics.
Main Results:
- Patient non-compliance and frequent dosing are significant barriers to effective schizophrenia management.
- Newer antipsychotics offer improved efficacy and reduced side effects but still use conventional delivery.
- Novel sustained and controlled-release systems hold potential for improved outcomes.
Conclusions:
- Novel drug delivery systems for antipsychotics are essential for improving patient compliance.
- These systems can reduce dosing frequency, enhance bioavailability, and reduce symptom recurrence.
- Future research should focus on developing and implementing advanced delivery methods for schizophrenia treatment.